At the NIH, SBIR/STTR spending limits have increased to more than $1B in 2018. SBIR eligibility includes small businesses that are majority-owned by VCOCs. Funding for Direct-to-Phase II activities have returned and non-financial advisory services are now offered to small businesses to help them advance their product development programs.
The path to commercialization is not met by funding alone, and many early stage companies require additional resources and networking opportunities to push their technologies forward. This panel will illustrate how strategic initiatives at the NIH and collaborations with third party investors/strategic partners impact the development of federally-funded technologies to reach patients, clinicians and the market to benefit human health.
Ability Level: All
Session ID: 503332